Stock 6446 PHARMAESSENTIA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
424 TWD +1.68% Intraday chart for PharmaEssentia Corporation +3.79% +22.54%
May. 13 PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 26 PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • With an expected P/E ratio at 86.12 and 33.21 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
+22.54% 4.37B -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
B+
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
B+
ARGENX SE Stock argenx SE
-1.69% 21.78B
B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6446 Stock
  4. Ratings PharmaEssentia Corporation